Summary:
The purpose of this study is to determine the safety and efficacy of TRx0237 8 mg/day in the treatment of subjects with mild Alzheimer's Disease compared to placebo.
Qualified Participants Must:
• Be under 90 years old
•
Have Memory loss
•
Have the availability of a study partner
Qualified Participants May Receive:
May be compensated for time and travel.